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Available online 24 March 2016Background: Critical limb ischemia (CLI) is a major health problemwith no adequate treatment. Since CLI is char-
acterized by insufﬁcient tissue vascularization, efforts have focused on the discovery of novel angiogenic factors.
Cyclophilin A (CyPA) is an immunophilin that has been shown to promote angiogenesis in vitro and to enhance
bonemarrow (BM) cell mobilization in vivo. However, its potential as an angiogenic factor in CLI is still unknown.
Thus, this study aimed to evaluate whether CyPA might induce neo-angiogenesis in ischemic tissues.
Methods and results:Wild-type C57Bl/6j mice underwent acute hind-limb ischemia (HLI) and received a single
intramuscular administration of recombinant CyPAor saline. Limbperfusion, capillary density and arteriole num-
ber in adductor muscles were signiﬁcantly increased after CyPA treatment. Interestingly, BM-derived CD117+
cell recruitment was signiﬁcantly higher in ischemic adductor tissue of mice treated with CyPA versus saline.
Therefore, the effect of CyPA on isolated BM-derived CD117+ cells in vitro was evaluated. Low concentrations
of CyPA stimulatedCD117+ cell proliferationwhile high concentrations promoted cell death.Moreover, CyPA en-
hanced CD117+ cell adhesion and migration in a dose-dependent manner. Mechanistic studies revealed that
CyPA up-regulated CXCR4 in CD117+ cells and in adductor muscles after ischemia. Additionally, SDF-1/CXCR4
axis inhibition by the CXCR4 antagonist AMD3100 decreased CyPA-mediated CD117+ cell recruitment in the
ischemic limb.
Conclusion: CyPA induces neo-angiogenesis by recruiting BM-derived CD117+ cell into ischemic tissues, at least
in part, through SDF-1/CXCR4 axis.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Hind-limb ischemia1. Introduction
Critical limb ischemia (CLI) represents a social and medical problem
with no effective pharmacologic therapy available [1]. Since it is charac-
terized by impaired vascularization of the lower extremities, therapeu-
tic angiogenesis has been proposed as a novel treatment strategy [2–5].
Emerging data suggest the therapeutic potential of bone marrow
(BM)-derived stem/progenitor cells in limb ischemia [6,7]. In particular,
a BM-derived cell population expressing the stem cell factor receptor
CD117 has been reported to be recruited into the ischemic limb tissue
to promote neovascularization [8,9]. Different mechanisms by which
these cells contribute to the revascularization of the ischemic tissueRegenerative Medicine, Centro
128 Milan, Italy.
land Ltd. This is an open access articlhave been proposed including paracrine actions [10–14] and/or ability
to differentiate into endothelial cells [15].
Recently, it has been reported that the chemokine stromal cell-
derived factor-1α (SDF-1) and its speciﬁc receptor CXC chemokine re-
ceptor 4 (CXCR4), which is expressed at high levels on CD117+ cells,
play critical roles in the recruitment of these cells in a mouse model of
hind-limb ischemia (HLI) [16–18].
An important mediator of the SDF-1/CXCR4 axis is Cyclophilin A
(CyPA), a ubiquitously distributed protein belonging to the
immunophilin family. Like other cyclophilin family members, CyPA
has peptidyl–prolyl cis–trans isomerase activity, which regulates pro-
tein folding and trafﬁcking [19]. In particular, intracellular CyPA plays
a key role in CXCR4-mediated signalling such as nuclear export of het-
erogeneous nuclear ribonucleoprotein A2, activation and nuclear trans-
location of extracellular-signal-regulated kinase 1/2 (ERK1/2), and
chemotactic cell migration [20]. Notably, we found that CyPA inducese under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pertrophic hearts [22] of ApoE−/− mice. In addition, CyPA was found
to be upregulated in murine adductor muscles after HLI [23].
Although CyPA was initially believed to function primarily as an in-
tracellular protein, recent studies revealed that it can be secreted by
cells in response to inﬂammatory stimuli [24–26]. Extracellular CyPA is
a potent leukocyte chemoattractant for human monocytes, neutrophils,
eosinophils, and T cells [27,28]. We have shown that extracellular CyPA
stimulates pro-inﬂammatory signals in endothelial cells [21,29] and
others have reported that CyPA increases endothelial cell proliferation,
migration, invasive capacity, and tubulogenesis in vitro [30]. Importantly,
plasma CyPA levels were found to be signiﬁcantly increased in patients
with inﬂammatory diseases including peripheral artery disease [31–33].
We speculated that CyPA may modulate ischemia-induced neo-
angiogenesis, based on experimental evidence underlying the impor-
tance of CyPA in the SDF-1/CXCR4 axis, the enhanced expression in
HLI, the ability to promote BM cell mobilization or recruitment in vivo
and to modulate angiogenesis in vitro.
Here, we provide new insight into the mechanisms by which extra-
cellular CyPA regulates BM-derived CD117+ cell functions in the pro-
cess of neovascularization of ischemic limb tissues and we show that
CyPA might offer a new strategy to treat limb ischemia.
2. Materials and methods
2.1. Animal procedures
All animal studieswere conducted in conformitywith the guidelines
from Directive 2010/63/EU of the European Parliament on the protec-
tion of animals used for scientiﬁc purposes or the NIH guidelines, and
in accordance with experimental protocols approved by the University
Committee on Animal Resources at the University of Milan. Animals
were housed under a 12 h light/dark regimen. All mice were genotyped
by PCR of tail clip samples.
2.2. In vivo procedures
Wild-type (WT) male mice, 8-week-old on a C57Bl/6j background
were anaesthetized with an intraperitoneal injection of a mixture con-
taining medetomidine 0.5 mg/kg and ketamine 100 mg/kg, and hind-
limb trichotomy was performed. A surgical skin incision was made in
the left inguinal region, starting from the groin and ﬁnishing at the
level of the bifurcation of saphenous and popliteal arteries. After skin
incision, the subcutaneous fat pad of the hind-limb was removed and
the femoral artery was isolated from the saphenous nerve and vein,
both of them were kept intact. Arterial ischemia was induced by
electrocoagulation of two femoral artery sites: a proximal site, below
the branch of external iliac artery, and a distal site, in the bifurcation
of saphenous and popliteal arteries. This artery segmentwas completely
removed. Contralateral non-ischemic hind-limbs were used as control.
At the time of surgery, 10 ng of recombinant human CyPA (R&D Sys-
tems) was injected in ischemic adductor muscles at ﬁve different sites
(10 μl/injection) along the projection of the femoral artery.
For AMD3100 treatment, Alzet® Osmotic Pumps (Alzet®) were im-
planted in mice to continuously deliver AMD3100 (360 μg/day) or an
equivalent volume of saline over a period of 3 days. Mice that
underwent osmotic pump implantation were previously anaesthetized
with intraperitoneal injection of medetomidine 0.5 mg/kg and keta-
mine 100 mg/kg.
Carprofen (5mg/kg body weight) was given by intramuscular injec-
tion to provide post-operative analgesia.
2.3. Limb perfusion in mice after ischemia
At 0, 3, 7, 14, and 21 days post-ischemia, mice were anaesthetized
with an intraperitoneal injection of amixture containingmedetomidine0.5 mg/kg and ketamine 100 mg/kg and blood ﬂow ratios in the ische-
mic (left) versus control (right) limbs were measured using a laser
Doppler PeriScan PIM II Imager (Perimed AB). Images were obtained
by two operators blinded to the treatment and analysed with PeriScan
System Software — LPDIwin (Perimed AB). Data represent ischemic/
contralateral non-ischemic hind-limb ratios.
2.4. Immunoﬂuorescence
Mice were anaesthetized, perfused with normal saline and then
ﬁxed with 10% phosphate-buffered formalin for 10 min at 100 mm/Hg,
via left ventricle. Fixed adductor muscles were parafﬁn embedded and
5-μm-thick sections were cut from each sample with muscle ﬁbres ori-
ented in the transverse direction. Capillary density was determined by
counting the capillary structures in 30–40 random ﬁelds using an anti-
body against CD31 (BD Bioscience). In other sections, arterioles were
identiﬁed by using an antibody against α-smooth muscle actin
(AbCam) and counted. Counts were performed by two readers blinded
to the treatment and similar results were obtained. Analyses were per-
formed using a Zeiss LSM 710 confocal microscope. The number of capil-
laries and arterioles was normalized to the section area calculated with
ZEN 2008 software (Carl Zeiss).
2.5. Immunohistochemistry
Formaldehyde-ﬁxed parafﬁn sections were incubated with the pri-
mary antibody overnight (O/N) at 4 °C. Antibodies raised against CyPA
(Santa Cruz Biotechnology), CD117 (Cell Signaling Technology), CD45
(BD Bioscience), Mac-3 (BD Bioscience), and CD3 (BD Bioscience)
were used. As a negative control, species- and isotype-matched IgGs
were incubated in place of the primary antibodies. Slides were viewed
with an AxioSkop microscope equipped with an AxioCam camera
(Carl Zeiss). Densitometric analyses were performed with AxioVision
4.7 software (Carl Zeiss) by two readers blinded to the treatment.
2.6. CyPA serum levels
Mice were anaesthetized by 2% isoﬂurane and blood samples were
collected by retro-orbital puncture. Serum was obtained from blood
samples at 0, 3, 7, 14, and 21 days after ischemia. CyPA serum levels
were detected with an ELISA kit (USCN Life Science Inc.) following the
manufacturer's instructions.
2.7. Cell isolation and culture
8-Week-old male WT (C57Bl/6j) mice were anaesthetized with 2%
isoﬂurane and euthanized by cervical dislocation. BM-derived CD117+
cells were isolated by ﬂushing the BM of femurs and tibiae. Thereafter,
immune-magnetic cell sorting was conducted by using CD117
MicroBeads following the manufacturer's instructions (MACS; Miltenyi
Biotech). Only preparations with N90% BM-derived CD117+ cells were
used. Cells were grown in StemSpan SFEM Medium supplemented
with the StemSpan CC100 Cocktail containing IL-3, IL-6, SCF and FLT3
(STEMCELL Technologies).
2.8. BM-derived CD117+ cell recruitment
BM-derived CD117+ cells were isolated as reported above and incu-
bated O/N in StemSpan SFEMMedium. The day after, cells were labelled
with the CellTrace™ Carboxyﬂuorescein succinimidyl ester (CFSE) re-
agent (Life Technologies) following the manufacturer's instructions.
BM-derived CD117+ labelled cells (6 × 105 cells) were resuspended in
200 μl saline solution and injected retro-orbitally in each ischemic
mouse (5 treated with CyPA, 5 treated with saline). Two days after in-
jection, mice were anaesthetized, perfused with normal saline and
then ﬁxed with 10% phosphate-buffered formalin for 10 min at
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washedO/Nwith Phosphate Buffer Saline (PBS; Gibco), treatedwithdif-
ferent concentrations of sucrose (Sigma-Aldrich) solutions (ranging
from 15% to 30%), and embedded in OCT (Bio-Optica). 5-μm-Thick
cryo-sections were cut from each sample with muscle ﬁbres oriented
in the transverse direction. To evaluate whether recruited BM-derived
CD117+ cells co-express an endothelial marker, an immunoﬂuores-
cence assay was performed with an anti-CD31 antibody (BD Biosci-
ence). Nuclei were stained with Hoechst 33342 (Life Technologies) for
10 min. Analyses were performed by two blinded operators with the
AxioObserver Z.1 microscope (Carl Zeiss) equipped with an AxioCam
MRmcamera (Carl Zeiss). Fluorescence intensitywasnormalized to sec-
tion area by using the image analyser AxioVision 4.7 software (Carl
Zeiss).
2.9. Cell proliferation
BM-derived CD117+ cellswere plated at a density of 2 × 105 cells/ml
(96-well plate; Costar) and incubated with exogenously added CyPA at
different concentrations (ranging from 10 ng/ml to 1000 ng/ml) or ve-
hicle. Cell counting was performed by an investigator blinded to the
treatment protocol. Cell proliferation was measured daily from day 1
to day 5 by cell counting in the presence of Trypan blu (Sigma-Aldrich).
2.10. Cell death and cycle
CyPA effect on BM-derived CD117+ cell death and cell cycle were
evaluated following serum deprivation for 48 h in RPMI medium
(Gibco) and upon exposure to exogenously added CyPA (ranging from
10 ng/ml to 1000 ng/ml).
For cell death experiments, after treatment cells were resuspended
in FACS buffer (0.1% Bovine Serum Albumin, BSA and 5 mM EDTA in
PBS) and incubated with AnnexinV-FITC antibody (eBioscience) for
10 min at room temperature. Then, cells were washed, resuspended in
FACS buffer and incubated with 20 μg/ml of Propidium Iodide (PI;
eBioscience).
FACS analysis was performed with a Gallios ﬂow cytometer
(Beckman Coulter). Data from 10,000 events per sample were collected
and the percentage of the elements was calculated using Kaluza soft-
ware (Beckman Coulter).
The cell cycle distribution after cell starvationwas evaluated by ﬂow
cytometry by bromodeoxyuridine/PI (BrdU/PI) assay. Brieﬂy, cells were
treated with BrdU (Sigma) solution at a ﬁnal concentration of 30 μM for
1 h in a CO2 incubator at 37 °C. Then, cells were washed in PBS, resus-
pended in PBS, ﬁxed with 95% ethanol, and stored O/N at 4 °C. The day
after, cells were pelleted, treated with 2 N HCl (Sigma), 0.2% Triton
X-100 (Sigma) for 30 min at room temperature and then resuspended
with 0.1 M Na2B4O7 (Sigma), pH 8.5 to neutralize acid. Cells were
washed in PBS, 0.1% BSA, 0.5% Tween 20 (Sigma), and incubated with
antibody anti-BrdU-FITC (BD Bioscience) for 30 min at room tempera-
ture. Cells were centrifuged and resuspended in PBS containing
5 ng/ml of PI (Sigma). FACS analysis was performed with a Gallios
ﬂow cytometer (BeckmanCoulter). Data from20,000 events per sample
were collected and the relative percentages of the cells in G0/G1, S, and
G2/M phases of the cell cycle were calculated using Kaluza software
(Beckman Coulter).
2.11. Adhesion assay
BM-derived CD117+ cells were treated with increasing concentra-
tions of CyPA (from 10 ng/ml to 1000 ng/ml) for 20 h in StemSpan
SFEMMedium. 96-Well plateswere coatedwith 10 μg/mL of ﬁbronectin
(Sigma-Aldrich) O/N at 4 °C. The day after, wells were washed 2 times
with PBS, blocked for 2 h with 1% BSA (Sigma-Aldrich) and washed
again with PBS. Treated BM-derived CD117+ cells (5 × 105 in 100 μl)
were added to each well and allowed to adhere for 3 h. Each well waswashed with PBS with Ca2+/Mg2+ (Gibco) to remove debris and ﬂoat-
ing cells, then adherent cells were ﬁxed for 10 min with 10% formalin
and again washed 3 times. Cells were stained with 0.05% Crystal Violet
(Sigma-Aldrich) for 30 min and washed 3 times with distilled water.
To quantify the cell number, the dye was solubilized with methanol
and the OD of each well was quantiﬁed at 540 nm with an absorbance
plate reader Mithras LB 940 (Berthold Technologies).
2.12. Migration assay
BM-derived CD117+ cells (1 × 106) were seeded into the upper
chamber of a transwell plate with a pore size of 3 μm (Sigma-Aldrich)
in Migration Medium (0.1% FCS, 25 mmol/l HEPES in RPMI). CyPA
100 ng/ml was added to the lower chamber of the transwell plate. Cell
migration towards CyPA was determined after 4 h of incubation at
37 °C. The number of migrating cells was determined by the Crystal
Violet (Sigma-Aldrich) assay as reported above or by cell counting in
the presence of Trypan blue. Migration was calculated by dividing the
number of cells which traversed the transwell membrane in the pres-
ence of CyPA by the number of cells which migrated in response tome-
dium alone. Cell countingwas performed by an investigator blind to the
treatment protocol.
2.13. Differentiation assay
BM-derived CD117+ cells were seeded at a cell density of 2.5 × 105
and treatedwith CyPA (100 ng/ml) as previously described [34]. Brieﬂy,
cells were cultured on 6-multiwell plates coated with 20 μg/ml ﬁbro-
nectin (Sigma) in IMDMmedium (Gibco) supplemented with 20% FBS
(Lonza) and vascular endothelial growth factor (VEGF, 20 ng/ml), ﬁbro-
blast growth factor-1 (FGF-1, 20 ng/ml), and insulin growth factor-1
(IGF-1, 20 ng/ml) (Peprotech). Cells were cultured for 7 days and the
mediumwas changed every 2 days. BM-derived CD117+ cell differenti-
ation towards the endothelial lineage was determined by ﬂow cytome-
try. Cells were collected, washed with the previously described FACS
buffer and incubated with CD31-PE (BD Bioscience) and CD45-PerCP
(clone 30-F11, BD Bioscience) antibodies. FACS analysis was performed
with a Gallios ﬂow cytometry (Beckman Coulter). Data from 10,000
events per sample were collected and percentage analyses were per-
formed by Kaluza software (Beckman Coulter).
2.14. CD117+ cell tube formation assay
BM-derived CD117+ cells were seeded onto a Cultrex (Cultrex Re-
duced Growth Factor BasementMembrane Extract, Trevigen Inc.) artiﬁ-
cial cell basal membrane as previously reported [35]. Brieﬂy, Cultrex
(250 μl) was allowed to polymerize onto 12-well plates at 37 °C, 5%
CO2 for 30 min. BM-derived CD117+ cells were seeded at a concentra-
tion of 5 × 104 cells/well in IMDM medium (Gibco) supplemented
with 20% FBS (Lonza) and VEGF (20 ng/ml), FGF-1 (20 ng/ml), and
IGF-1 (20 ng/ml) (Peprotech) for 7 days.
2.15. mRNA extraction and qRT-PCR
BM-derived CD117+ cells were treated for 16 h with recombinant
CyPA (ranging from 10 ng/ml to 1000 ng/ml). RNA was isolated with a
Total RNA Puriﬁcation kit (Norgen Biotek Corp.). For in vivo analysis, ad-
ductor muscles were harvested and RNAwas isolated with an RNeasy®
Microarray Tissue Kit (Qiagen). RNA quantiﬁcation was determined
with a spectrophotometer (ND-1000, NanoDrop®, EuroClone®).
Reverse transcription was conducted with the SuperScript III
(Invitrogen™) following the manufacturer's instructions. qRT-PCR was
performed with the use of the iQTM SYBR Green Super Mix (BIO-RAD)
and RT2 qPCR Primers (Qiagen). All reactions were performed in a 96-
well formatwith the iQ5TM (BIO-RAD). The relative quantities of speciﬁc
mRNAs were obtained with the use of the comparative Ct method and
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(GAPDH).2.16. Western blot analysis
Adductormuscle tissues andBM-derived CD117+ cellswere lysed in
cell lysis buffer (Cell Signaling Technology) supplemented with a prote-
ase inhibitor cocktail (Sigma Aldrich). Total cell proteins were subjected
to SDS-PAGE and transferred onto a nitrocellulose membrane. The
membranes were blocked for 1 h at room temperature in 5% non-fat
dry milk in Wash Buffer (0.1% Tween 20 in Tris Buffer Sulfate) and
then incubated O/N at 4 °C with the appropriate primary antibody.
The primary antibodies used were speciﬁc for CyPA (Sigma Aldrich),
CXCR4 (Abcam), phospho-CXCR4 (Abcam), protein kinase B (AKT, Cell
Signaling Technology), phospho-AKT (Cell Signaling Technology),
ERK1/2 (Santa Cruz Biotechnology), phospho-ERK1/2 (Cell Signaling
Technology), and tubulin (Sigma Aldrich). The membranes were incu-
bated with peroxidase-conjugated secondary antibodies for 1 h. Signals
were visualized using enhanced chemiluminescence Western blotting
detection system (GE Healthcare). Images were acquired with the Alli-
anceMini 2M (UVITec Cambridge), and densitometric analysis of mem-
braneswas performed using the AllianceMini 4 16.07 software (UVITec
Cambridge). Proteins were normalized according to α-tubulin and/or
GAPDH.2.17. Statistical analyses
Quantitative results are expressed as mean ± SD. Statistical signiﬁ-
cance was evaluated with GraphPad Prism 5.
Variables were analysed by Student's t test. A value of p ≤ 0.05 was
deemed statistically signiﬁcant.Fig. 1. Intracellular and extracellular levels of CyPA increase duringHLI. CyPA gene (A) and prote
blot quantiﬁcation data aremean± SD, n=5/group/time point). (D) Representative images of
(left panel) adductor muscle sections 3 days after HLI. (E) Serum levels of CyPA at different t
Magniﬁcation = 20×. Scale bar = 100 μm.3. Results
3.1. CyPA levels increase during HLI
To evaluate the potential involvement of CyPA during the in vivo re-
sponse to ischemia, we used an established mouse model of HLI
consisting of the unilateral removal of the femoral artery. Interestingly,
the endogenous expression of CyPA in the adductor muscle of WTmice
was remarkably increased 3 days after ischemia and peaked at 7 days
post-surgery. This effect was evident both at RNA (Fig. 1A) and protein
(Fig. 1B, C and D) levels.
Since CyPA is a protein secreted in response to inﬂammatory stimuli
[36] and limb ischemia is a pathologic condition characterized by ele-
vated inﬂammation in the injured muscle, we evaluated whether
CyPA is also secreted during HLI. Serum levels of CyPA rose after ische-
mia (Fig. 1E) suggesting that it might be secreted in order to modulate
the in vivo response to HLI.3.2. Local administration of CyPA increases limb perfusion and neo-
angiogenesis
The CyPA expression and secretion data prompted us to evaluate the
effect of exogenously administered recombinant CyPA in the neo-
angiogenic response to ischemia. Speciﬁcally, CyPA (10 ng) was locally
injected in the ischemic muscle immediately after HLI. To evaluate
whether CyPA affects neo-angiogenesis, hind-limb perfusion, capillary
density and arteriole number were analysed.
As depicted in Fig. 2A and B, exogenous CyPA signiﬁcantly improved
bloodﬂow vs. saline 0, 3, 7, 14, and 21days after HLI. Furthermore, in ad-
ductor muscles treated with CyPA, a signiﬁcant increase both in capil-
lary density (Fig. 2C and D) and arteriole number (Fig. 2E and F) was
observed 7 days after ischemia.in (B, C) expression at different days afterHLI (qRT-PCRdata are fold change±SD,Western
immunohistochemistry for CyPA in ischemic (right panel) and contralateral non-ischemic
ime points after HLI (data are mean ± SD, n = 5/time point). Student's t-test: *p b 0.05.
Fig. 2. CyPA increases limb perfusion and angiogenesis. (A) Representative contrast images (upper panels) and correspondent laser Doppler images (lower panels) of hind-limbs 3 days
after surgery and treatments. Colour scale inDoppler images represents a gradient from less perfused (blue) to highly perfused (red) areas. (B) Bar chart of perfusion rates ondifferent days
post-HLI. (C) CD31 immunoﬂuorescence for capillary detection and relative quantiﬁcation (D) 7 days post-surgery. Magniﬁcation = 40×. Scale bar = 15 μm. (E) α-smooth muscle actin
(α-SMA) immunoﬂuorescence and relative arteriole quantiﬁcation (F) 7 days post-surgery. Magniﬁcation = 20×. Scale bar = 40 μm. All data are mean ± SD, n= 5/group/time point.
Student's t-test: *p b 0.05.
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CyPA improves post-ischemic reparative neovascularization and blood
ﬂow recovery in WT mice.
3.3. CyPA augments the number of inﬂammatory cells following HLI
Key cellular processes observed during an ischemic stimulus are the
activation, recruitment, and invasion of a number of inﬂammatory cells
that are involved in inducing and promoting angiogenesis by releasing
multiple pro-angiogenic cytokines, chemokines and growth factors
[37]. Thus, we evaluated the involvement of CyPA in the recruitment
of inﬂammatory cells into ischemic tissue.
CyPA treatment increased the number of leukocytes (CD45+ cells;
Fig. 3A and B), macrophages (Mac-3+ cells; Fig. 3C and D) and T cells
(CD3+ cells; Fig. 3E and F) into the ischemic tissue at 3 days post-
surgery. It is worth noting that inﬂammation decreased in CyPA-
treated mice at longer time points post-ischemia (14 days, data not
shown), suggesting that CyPA did not exacerbate a chronic and delete-
rious inﬂammatory process.
Collectively, these experimentalﬁndings imply that exogenousCyPA
accelerates an inﬂammation-driven neoangiogenic process favouring
tissue repair.3.4. CyPA regulates the recruitment of CD117+ cells following HLI
Emerging data suggest the clinical potential of CD117+ cells to re-
store blood ﬂow to the ischemic limb [6,7,18]. Thus, we measured the
number of these cells after HLI in the presence or absence of CyPA. Inter-
estingly, CyPA signiﬁcantly increased the number of CD117+ cells in is-
chemic muscles compared to saline-treated group (Fig. 4A and B).
Consistently, an increased expression of the gene encoding CD117
(Fig. 4C) and its protein (Fig. 4D and E) was observed after 3 days
from the initial treatment with CyPA, administered at the time of the
surgery. This result is likely due to their increased recruitment in the is-
chemic tissue. To evaluate whether the increased number of cells was
linked to the capacity of CyPA to act as chemoattractant, CD117+ cells
were isolated frommouse BM and labelled with the green ﬂuorescence
marker CFSE CellTraceTM reagent. Subsequently, these cells were deliv-
ered by retro-orbital injection in the venous sinus of WT mice (6 × 105
cells/mouse) at day 1 post-ischemia (Fig. 5A). Intravenously adminis-
tered CD117+ cells were detected in adductor muscles harvested
3 days post-ischemia along with the endothelial marker CD31 (Supple-
mentary Fig. 1S). CFSE-positive cells were typically found in small clus-
ters in the border zone of the ischemic tissue and their recruitment into
the ischemic tissue was signiﬁcantly increased in mice treated with
Fig. 3. CyPA augments inﬂammatory cell number following HLI. Immunohistochemistry for CD45 (A), Mac-3 (C), and CD3 (E) on adductor muscle slices of ischemic mice
treated with saline or with 10 ng CyPA for 3 days. Immunohistochemistry quantiﬁcation (B, D, F) data are shown as mean ± SD, n = 5/group. Student's t-test: *p b 0.05.
Magniﬁcation = 20×. Scale bar = 40 μm.
329G.L. Perrucci et al. / International Journal of Cardiology 212 (2016) 324–335CyPA compared to saline (Fig. 5B and C). Taken together these results
indicate that CyPA modulates the recruitment of CD117+ cells.
3.5. CyPA is involved in CD117+ cell survival, adhesion and migration
in vitro
Based on experimental evidence underlying the importance of CyPA
in the recruitment of CD117+ cells into ischemic tissue, we next evalu-
ated the effect of CyPA on isolated CD117+ cells in vitro.
Hence, CD117+ cells were isolated from the BM ofWTmice and the
ability of exogenous CyPA to directly stimulate these cells was tested at
different concentrations (10, 100 and 1000 ng/ml) and time points (0,
24, 48, and 72 h). A low concentration (100 ng/ml) of CyPA induced
the proliferation of CD117+ cells, while the higher concentration
(1000 ng/ml)was effective in reducing cell number (Fig. 6A). This effect
was signiﬁcant (p b 0.05) after 48 h and 72 h of treatment.
We further analysed whether the reduced number of CD117+ cells
due to a high concentration of CyPA was related to a cell cycle progres-
sion block (anti-proliferative effect) and/or to the occurrence of cell
death (cytotoxicity). Cell cycle distribution analysis of CD117+ cells ex-
posed to increasing doses of CyPA revealed no signiﬁcant differences incell cycle distribution between control and treated cells (Supplemental
Fig. 2S). However, CD117+ cell death analysis following serum depriva-
tion for 48 h and upon exposure to exogenous CyPA revealed that while
100 ng/ml CyPA decreased the number of AnnexinV−/PI+ cells,
1000 ng/ml CyPA exacerbated necrosis (Fig. 6D). In accordancewith re-
sults regarding cell proliferation, these data further establish that the
behaviour of CyPA on CD117+ cells is biphasic, exerting both positive
and negative effects depending on its concentration.
Since both migration and the subsequent adhesion of BM-derived
cells occur into the newly vascularized tissue during the formation of
new blood vessels after ischemia [38], we next tested the effects of
CyPA on the migratory and adhesive activity of CD117+ cells. Intrigu-
ingly, exogenous CyPA directly stimulated the migration of CD117+
cells (Fig. 6B) and enhanced cell adhesion to ﬁbronectin-coated dishes
in a dose-dependent manner (Fig. 6C). Considering that CD117+ cells
are able to differentiate into endothelial cells [38], we appraised wheth-
er CyPAmight affect their differentiation potential. As shown in Fig. 6E,
CyPA did not increase the expression of CD31 and did not improve the
ability of CD117+ cells to form tubules in vitro (Fig. 6F).
Since the leukocyte fate of CD117+ cells is also important for the
neoangiogenesis process, we evaluated whether CyPA could affect
Fig. 4. CyPA increases the number of BM-derived CD117+ cells. Immunohistochemistry for CD117 on adductor muscle sections of ischemic mice treated with saline or with 10 ng CyPA
(A) and relative quantiﬁcation (B). Ischemic sampleswere collected 7 days after HLI. Data are shown asmean±SD, n=5/group. CD117 gene (C) and protein (D, E) expression in adductor
muscle tissues (qRT-PCR data are fold change ± SD, Western blot quantiﬁcation data are mean ± SD, n= 5/group). Student's t-test: *p b 0.05. Magniﬁcation = 40×. Scale bar = 50 μm.
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alter the expression of this pan leukocyte marker (Fig. 3S).
These results clearly suggest that the main mechanism of action for
CyPA is to increase the survival, migration, and adhesion of CD117+
cells instead of promoting differentiation towards the endothelial
lineage.
3.6. CyPA regulates CXCR4 expression and activity in vitro and in vivo
In light of the major importance of SDF-1/CXCR4 signalling in the
regulation of BM-derived CD117+ cell recruitment and neo-
angiogenesis during ischemia [16,18], we examined whether CyPA
modulates CXCR4 expression. CD117+ cells exposed to increasing con-
centrations of CyPA for 16 h exhibited a progressive increase in CXCR4
mRNA levels (Fig. 7A). However, the highest dose of CyPA
(1000 ng/ml) did not induce CXCR4 gene up-regulation, probably due
to cytotoxic effects shown above.
In addition, CyPA increased CXCR4 protein activation (phosphoryla-
tion at serine 346, Fig. 7B and C) and consequently its downstream
signalling pathway (ERK1/2 and AKT, Fig. 7B). Inhibition of the SDF-1/
CXCR4 axis by the CXCR4 antagonist AMD3100 decreased CyPA-
mediated activation of CXCR4 cell signalling (Fig. 7B and C).
The critical role for SDF-1/CXCR4 pathway in CyPA-mediated effects
was corroborated in the murine model of HLI. In particular, ischemic
muscles of mice treated with CyPA showed increased CXCR4 gene
(Fig. 7D) and protein expression (Fig. 7E–F and Supplementary
Fig. 4S). Interestingly, CyPA also induced the up-regulation of SDF-1
gene expression (Fig. 7G) and its serum levels (Fig. 7H).
These data demonstrate that CyPA modulates the SDF-1/CXCR4
pathway in CD117+ cells during HLI.
3.7. Inhibition of SDF-1/CXCR4 signalling reverses CyPA-mediated neo-
angiogenesis in vivo
To substantiate that the action of CyPA during HLI is mainly
mediated by the SDF-1/CXCR4 axis, neo-angiogenesis was determinedafter CXCR4 blockade with the antagonist AMD3100. AMD3100
(360 μg/day) was infused continuously over 3 days via an implanted
osmotic mini-pump. At day 1, mice underwent HLI and treatment
with CyPA or saline. After 4 days, ischemic adductor muscles were
harvested to measure tissue neovascularization. Results revealed that
AMD3100 abrogated the CyPA-mediated increase in blood perfusion
(Fig. 8A) as well as capillary density (Fig. 8B) and arteriole number
(Fig. 8C).
Additionally, the inﬂux of BM-derived CD117+ cells into injured ad-
ductormuscles was not signiﬁcantly increased in the AMD3100+CyPA
treatment group compared to mice receiving AMD3100 alone (Fig. 8D
and E).
Altogether, these results suggest that CyPA drives the angiogenic re-
sponse to ischemia, at least in part, through the SDF-1/CXCR4 signalling
pathway.
4. Discussion
The present study addressed the role of CyPA as a novel agent regu-
lating ischemia-induced neo-angiogenesis. Speciﬁcally, we demonstrat-
ed that the treatment of ischemic hind-limbs with exogenous CyPA
improves tissue revascularization and repair. Notably, blood ﬂow perfu-
sion and new blood vessel formation were signiﬁcantly accelerated in
mice treated with CyPA compared with saline.
Our results were surprising and counter-intuitive because we al-
ways considered CyPA as a pro-inﬂammatory cytokinemediating tissue
damage. Nonetheless, recent insights have shed light on the cellular and
molecular processes through which conventional inﬂammatory cyto-
kines (e.g. IL-6 and TNFα) promote tissue repair and regeneration
[39]. In this regard, we believe that CyPA levels increase during HLI to
promote reparative inﬂammation. Indeed, we found that CyPA in-
creases the number of inﬂammatory cells into ischemic limbs. These re-
sults are consistent with a recent evidence which highlights the tight
interconnection between the processes of inﬂammation and angiogen-
esis [37]. It has been established that newly formed blood vessels enable
the continuous recruitment of inﬂammatory cells, which release a
Fig. 5. CyPA enhances BM-derived CD117+ cell recruitment in ischemic mice. (A) Methodological approach for HLI surgery and BM-derived CD117+ cell isolation, labelling, and retro-
orbital injection. WT C57Bl/6j mice underwent surgical femoral artery removal by cauterization and dissection (recipient mice). Ischemic mice were treated by intramuscular injection
of saline solution (n = 5) or 10 ng CyPA (n = 5). The day after surgery, WT C57Bl/6j mice (n = 5; donor mice) were sacriﬁced to explant BM-derived selected CD117+ cells from
hind-limb bones. Once isolated, cells underwent CFSE labelling and injection into recipient HLI mice. (B) Representative images of CFSE-labelled BM-derived CD117+ cells (green) in
adductor muscle cryo-sections and relative signal quantiﬁcation (C). Highlighted areas correspond to 40× magniﬁcation. Data are shown as mean ± SD, n= 5/group. Student's t-test:
*p b 0.05. Magniﬁcation = 20×. Scale bar = 200 μm.
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and further promote angiogenesis. However, self-limiting tissue inﬂam-
mation is essential for proper restorative responses. In this regard, it is
important to point out that in our experimental setting CyPA did not
trigger a positive feedback loop which ultimately leads to chronic in-
ﬂammation. In fact, we observed that the inﬂammatory process acceler-
ated by CyPA was decreased 14 days after HLI; thus inﬂammation was
transient and not chronic in nature.
In addition to inﬂammatory cells, the process of neo-angiogenesis in
the ischemic limb critically involves BM-derived cells that incorporate
into the damaged blood vessel endothelium and promotes new blood
vessel formation [40]. Cells expressing the CD117marker have been ex-
tensively studied as haematopoietic and vascular progenitors in exper-
imental models of HLI. In particular, it was reported that these cells are
recruited into ischemic tissues and participate in the process ofrevascularization [8,9,18]. The transplantation of BM-derived CD117+
cells into ischemic hind-limbs was associated with improved
microvessel density and recovery of blood perfusion [8]. Interestingly,
CyPA signiﬁcantly improved CD117+ cell recruitment into ischemic tis-
sues. These ﬁndings led us to explore the direct effect of CyPA in cul-
tured CD117+ cells in vitro. We found that CyPA functionally
modulates CD117+ cells by enhancing proliferation, migration and ad-
hesion, critical steps of the neo-angiogenic process. Speciﬁcally, low
doses of CyPA augmented CD117+ cell proliferation in addition to en-
hanced cell migration and adhesion. Conversely, high doses of CyPA in-
duced cell death. This dose-dependent response to CyPA might be
related to the capacity of CyPA to induce the accumulation of reactive
oxygen species [21,22]. In fact, low doses of CyPA might increase low
levels of oxidative stress that can act as bona ﬁdemessengers to control
multiple cellular functions, including proliferation. On the other hand,
Fig. 6. CyPA is involved in BM-derived CD117+ cell survival, migration and adhesion. Assay graphs for cell number up to 72 h (A), migration up to 4 h (B), and adhesion after 24 h (C) of
treatmentwith increasing doses of CyPA. (D) FACS analysis reporting the percentage of AnnexinV negative and PI positive BM-derived CD117+ cells after serumdeprivation and treatment
with 100 ng/ml CyPA for 48 h. (E) FACS analysis and percentage of CD31 in BM-derived CD117+ cells after 7 days of treatment with 100 ng/ml CyPA. (F) Representative images of
tube formation assay in BM-derived CD117+ cells ± CyPA (100 ng/ml). Results are means ± SD of three experiments performed in triplicate. Student's t-test: *p b 0.05.
Magniﬁcation = 20×. Scale bar = 50 μm.
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species leading to cell death.
In our attempts to decipher the molecular mechanisms underlying
the process of CyPA-induced neo-angiogenesis, we found that CyPA
up-regulates the SDF-1/CXCR4 axis, a critical pathway involved in the
recruitment of BM-derived cells during peripheral limb ischemia [16].
The importance of the SDF-1/CXCR4 axis in BM-derived stem/progeni-
tor cell recruitment has been established with the observation that se-
lective expression of SDF-1 in injured tissue correlates with adult stem
cell recruitment and tissue regeneration [41]. Additionally, SDF-1 and
CXCR4 were recently reported to be expressed by or in close proximity
to angiogenic vessels in ischemicmuscles of patientswith peripheral ar-
tery disease, suggesting that SDF-1/CXCR4 signalling might be relevant
in post-natal neovascularization. The involvement of this pathway in
the process of angiogenesis was further conﬁrmed by Tachibana et al.
showing that CXCR4−/−mice die in utero and are defective in vascular
development, haematopoiesis and cardiomyogenesis [42].
Recently, it was reported that intracellular CyPA is essential for SDF-
1-mediated chemotactic actions [20] and cell survival [43]. However,
the effect of exogenous administered CyPA on CD117+ cells was never
investigated. Here, we found that CD117+ cells treated with exogenous
CyPA exhibited up-regulated expression of CXCR4, which paralleled
their migratory capacity in response to SDF-1. Moreover, we provided
evidence that CyPA directly regulates CXCR4 downstream events. Ex-
plicitly, we studied the role of CyPA on the modulation of ERK1/2 and
AKT activity, serine-threonine kinases that are involved in the CXCR4downstream intracellular pathway. We showed that exogenous CyPA
activates ERK1/2 and AKT and this effect was abrogated using the
CXCR4 antagonist AMD3100. These results demonstrated that CyPA,
by activating CXCR4, modulates ERK1/2 as well as AKT activity in
CD117+ cells.
In line with these in vitro ﬁndings, we found that exogenous CyPA
strongly up-regulates SDF-1 and CXCR4 gene expression in vivo.
Notably, CyPA-dependent CXCR4 up-regulation may have interesting
therapeutic implications. In fact, a recent study has demonstrated that
up-regulation of CXCR4 by gene transfer improves in vitro functional
properties of human endothelial progenitor cells and enhances arterial
re-endothelialization in mice subjected to carotid artery injury [44]. Re-
markably, the stimulatory effect of CyPA on neovascularization and
CD117+ cell recruitment was not observed when the SDF-1/CXCR4
axis was blocked by the infusion of AMD3100.
It is important to point out that in this study we focused on CD117+
cells since transplantation of these cells in the ischemic limb has been
reported to lead tomuscle and vascular regeneration [8,9,18]. However,
we cannot exclude that CyPA might induce neo-angiogenesis by acting
on other cell types by parallel mechanisms. We and others have shown
that CyPA increases endothelial cell and vascular smooth muscle cell
proliferation [29,45,46], as well as inﬂammatory cell recruitment [21,
26], both crucial and necessary mechanisms in the process of adult
neo-angiogenesis [47].
Therefore, in future investigations, we plan to address the effects of
CyPA on multiple cellular and biochemical targets during HLI.
Fig. 7. CyPA regulates CXCR4 expression and activity in vitro and in vivo. CXCR4 gene expression (A) in BM-derived CD117+ cells treated with CyPA. qRT-PCR was performed in triplicate
and data are shown as fold change ± SD. Western blot analysis (B) for active CXCR4 (phospho-CXCR4) and downstream mediators in BM-derived CD117+ cells treated for 5 min with
100 ng/ml CyPA and/or 25 μg/ml AMD3100. Cells were pre-treated with AMD3100 for 30 min before CyPA addition. Gene expression of CXCR4 (D) and SDF-1 (G) were evaluated in
adductor muscles of ischemic mice treated with saline or 10 ng CyPA (qRT-PCR data are fold change ± SD *p b 0.05; n = 5/group/time point). CXCR4 protein expression (E) was
analysed on adductor muscles by Western blot. Protein quantiﬁcation (C, F) was performed by densitometric analysis (*p b 0.05). SDF-1 levels (H) were measured by ELISA in the
serum of mice, 3 days after surgery and treatment with 10 ng CyPA. Student's t-test: *p b 0.05.
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The present study suggest that CyPA enhances neo-angiogenesis and
restore revascularization in ischemic tissues by regulating SDF-1/CXCR4
pathway and concomitantly modulating the recruitment of BM-derived
CD117+ cells (Supplementary Fig. 5S). Thus, CyPAmay serve as a useful
therapeutic strategy for accelerating angiogenesis in ischemic cardio-
vascular diseases, such as CLI.
Supplementary data to this article can be found online at http://dx.
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Fig. 8. Inhibition of CXCR4 signalling reverses CyPA-mediated neo-angiogenesis in vivo. Bar charts depict perfusion levels (A), number of capillaries (B), and arterioles (C) in mice treated
with saline, 10 ng CyPA, AMD3100 (360 μg/die) + saline or AMD3100 (360 μg/die) + 10 ng CyPA after 3 days post-surgery. Immunohistochemistry (D) and its densitometric analysis
(E) for CD117 in adductor muscle tissue sections from ischemic mice treated with AMD3100 or co-treated with 10 ng CyPA 3 days post-surgery. Data are means ± SD, n = 5.
Student's t-test: *p b 0.05. Magniﬁcation = 20×. Scale bar = 50 μm.
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